In conclusion, this study suggests that intratumoral CD103+ TILs represent an important prognostic biomarker for predicting better survival in patients with pSCC, and as such, may be a potential target candidate for the development of cancer immunotherapies. The gene discussed is ITGAE; the disease is cancer.